TY - JOUR
T1 - Institutional review of compliance with NCCN guidelines for breast cancer
T2 - Lessons learned from real-time multidimensional synoptic reporting
AU - Adegboyega, Titilayo O.
AU - Landercasper, Jeffrey
AU - Linebarger, Jared H.
AU - Johnson, Jeanne M.
AU - Andersen, Jeremiah J.
AU - Dietrich, Leah L.
AU - Driscoll, Collin D.
AU - Raghavendra, Meghana
AU - Madadi, Anusha R.
AU - Al-Hamadani, Mohammed
AU - Vang, Choua A.
AU - Marcou, Kristen A.
AU - Hudak, Jane
AU - Go, Ronald S.
N1 - Publisher Copyright:
© 2015 by the National Comprehensive Cancer Network. All rights reserved.
PY - 2015/2/1
Y1 - 2015/2/1
N2 - Background: Variations exist in compliance with NCCN Guidelines. Prior reports of adherence to NCCN Guidelines contain limitations because of lack of contemporary review and incomplete listing of reasons for noncompliance. Purpose: To assess institutional compliance and assist national quality improvement strategies through identifying valid reasons for noncompliance. Methods: Compliance with NCCN Guidelines was recorded prospectively using electronic synoptic templates for patients with newly diagnosed breast cancer treated at a single institution between January 2010 and December 2011. Compliance with NCCN Guidelines was recorded. The accuracy of real-time synoptic auditing methods compared with retrospective chart review and reasons for noncompliance was assessed. SAS 9.3 software was used for data analysis. Results: Compliance with NCCN Guidelines among 395 patients was 94% for initial staging evaluation, 97% for surgery, 91% for chemotherapy, 89% for hormone therapy, 91% for radiation therapy, 85% for follow-up, and 100% for determination of estrogen receptor/progesterone receptor and HER2 status. Age, comorbidities, and stage influenced guideline compliance. The most common reasons for noncompliance were patient refusal, patient choice after shared decision-making, and overuse of testing. Synoptic templated reporting was accurate in 97% patients. Conclusions: High compliance with NCCN Guidelines was demonstrated. Reasons for noncompliance were identifiable. Compliance and nonadherence can be evaluated quickly with electronic synoptic reporting. This allows real-time action plans to address quality concerns and aids national risk adjustment for comparison and benchmarking.
AB - Background: Variations exist in compliance with NCCN Guidelines. Prior reports of adherence to NCCN Guidelines contain limitations because of lack of contemporary review and incomplete listing of reasons for noncompliance. Purpose: To assess institutional compliance and assist national quality improvement strategies through identifying valid reasons for noncompliance. Methods: Compliance with NCCN Guidelines was recorded prospectively using electronic synoptic templates for patients with newly diagnosed breast cancer treated at a single institution between January 2010 and December 2011. Compliance with NCCN Guidelines was recorded. The accuracy of real-time synoptic auditing methods compared with retrospective chart review and reasons for noncompliance was assessed. SAS 9.3 software was used for data analysis. Results: Compliance with NCCN Guidelines among 395 patients was 94% for initial staging evaluation, 97% for surgery, 91% for chemotherapy, 89% for hormone therapy, 91% for radiation therapy, 85% for follow-up, and 100% for determination of estrogen receptor/progesterone receptor and HER2 status. Age, comorbidities, and stage influenced guideline compliance. The most common reasons for noncompliance were patient refusal, patient choice after shared decision-making, and overuse of testing. Synoptic templated reporting was accurate in 97% patients. Conclusions: High compliance with NCCN Guidelines was demonstrated. Reasons for noncompliance were identifiable. Compliance and nonadherence can be evaluated quickly with electronic synoptic reporting. This allows real-time action plans to address quality concerns and aids national risk adjustment for comparison and benchmarking.
UR - http://www.scopus.com/inward/record.url?scp=84923507767&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84923507767&partnerID=8YFLogxK
U2 - 10.6004/jnccn.2015.0026
DO - 10.6004/jnccn.2015.0026
M3 - Article
C2 - 25691610
AN - SCOPUS:84923507767
SN - 1540-1405
VL - 13
SP - 177
EP - 183
JO - JNCCN Journal of the National Comprehensive Cancer Network
JF - JNCCN Journal of the National Comprehensive Cancer Network
IS - 2
ER -